



FIG. 1



EC50	0.01063

FIG.2



C5 depleted hu serum + cyno serum
C5 depleted hu serum + hu serum
20% C5 depleted hu Serum
Alternative Pathway
% Hemolysis
125
100
75
50
25
0
0.00001
0.0001
0.001
0.01
0.1
1
10
100
serum dilution ~ xnM C5

FIG.3



20% Serum, Classical Pathway
% Hemolysis
nM Fab or Ab
0
25
50
75
100
125
1
10
100
1000
6525
6756
6757
6763
6952
6960
6961
7081
7082
7083
7084
7085
7086
7087
7088
7089
7090
7091
7092
7093
7094
Quidel α-C5
Quidel α-FP
Hu IgG
20% Serum

FIG.4



20% hu C5 depleted serum + 100pM C5, AP
% Hemolysis
nM Fab or Ab
0.01
0.1
1
10
100
1000
0
25
50
75
100
6525
6756
6757
6763
6952
6961
7081
7082
7083
7084
7086
7087
7088
7089
7090
7091
7092
7093
7094
5G1.1
Quidel α-C5
Quidel α-FP
Hu IgG
+0.1nM C5
C5-depleted serum

FIG.5




20% hu C5 depleted serum + 0.025% cyno serum, AP
% Hemolysis
0
25
50
75
100
0.1
1
10
100
1000
nM Fab or Ab
6525
6756
6757
6763
6952
6961
7081
7082
7083
7084
7086
7087
7088
7089
7090
7091
7092
7093
7094
Quidel a-C5
Quidel a-FP
Hu IgG
+0.1nM C5
C5-depleted serum

FIG.6




*100% lysis = 20% serum lysis

Max. inhibition (%):

MOR07091: 80
MOR07829: 95
MOR07830: 90
MOR07871: 90
MOR07872: 95
MOR07873: 97
MOR07874: 100
MOR07908: 97

FIG.7-1




*100% lysis = 20% serum lysis

Max. inhibition (%):

MOR07092: 100
MOR07831: 100
MOR07832: 100
MOR07875: 30
MOR07876: 100
MOR07877: 100
MOR07878: 100
MOR07879: 95
MOR07909: 100
MOR07910: 100

FIG.7-2




*100% lysis = 20% serum lysis

Max. inhibition (%):

MOR07093: 30
MOR07833: 75
MOR07834: 70
MOR07835: 60
MOR07836: 75
MOR07890: 65

FIG.7-3



*100% lysis = 20% serum lysis

Max. inhibition (%):
MOR07086: 95
MOR07864: 100
MOR07865: 100
MOR07866: 100
MOR07867: 100
MOR07868: 95
MOR07869: 100
MOR07870: 97

FIG.7-4



2SGI41_hemolytic assay CP_normalized*
5% cyno serum
MOR07091
MOR07829
MOR07830
MOR07871
MOR07872
MOR07873
MOR07908
% Lysis
c [nM]
*100% lysis = 5% cyno serum lysis

FIG.8-1



2SGI42_hemolytic assay CP_normalized*
5% cyno serum
MOR07092
MOR07831
MOR07832
MOR07876
MOR07878
MOR07909
MOR07910
% Lysis
c [nM]
*100% lysis = 5% cyno serum lysis

FIG.8-2



2SGI42_hemolytic ossay CP_normalized*
5% cyno serum
MOR07093
MOR07834
MOR07835
MOR03207
% Lysis
c [nM]
*100% lysis = 5% cyno serum lysis

FIG.8-3




2SGI41_hemolytic assay CP_normalized*
5% cyno serum
MOR07086
MOR07821
MOR07865
MOR03207
% Lysis
c [nM]
*100% lysis = 5% cyno serum lysis

FIG.8-4



	IC50
7086	0.07581
7821	0.04906
7822	0.07041
7823	0.07757
7824	0.3442
7092	0.4935
7831	0.05118
7832	0.03921
5G1.1	0.1400

FIG.9a

	IC50
7091	1.296
7829	0.4720
7830	0.4078
7093	2.823
7833	0.1161
7834	0.07866
7835	0.08439
7836	0.1694
7086	0.05113
5G1 1	0.1029






FIG.9b




	IC50
6763	38.66
7819	531.4
7820	2.535
7087	28.60
7826	153.3
7827	0.7352
7828	5.465
7086	0.06203
5G1.1	0.2054

FIG.9c



	IC50
6525	2.266
7813	42.74
7814	13.56
7816	3.760
7817	41.00
6757	121.0
7818	7.768
7085	0.06833

FIG.9d



	IC50
7086	0.121
7864	0.252
7865	0.0950
7866	0.116
7867	0.204
7868	0.505
7869	0.109
7870	0.328
7832	0.0530
7821	0.0879

FIG.9e




Hemolytic Assay: AP, 100pM Hu C5
Ser Hem
% Hemolysis
nM
0
25
50
75
100
0.01
0.1
1
10
100
7091
7871
7872
7873
7874
7832
7821
IC50
7091 3.75
7871 0.0545
7872 0.103
7873 0.134
7874 0.142
7832 0.0599
7821 0.0740

FIG.9f



	IC50
7092	1.65
7875	
7876	0.143
7877	0.219
7878	0.219
7832	0.0775
7821	0.104

FIG.9g





Hemolytic Assay: AP, 100pM Hu C5
% Hemolysis
Ser Hem
75
50
25
0
0.01
0.1
1
10
100
1000
nM Fab or Ab
7094
7880
7881
7882
7883
7884
7885
7818
7907
7832
IC50
7094 10.9
7880 0.0825
7881 0.0700
7882 0.235
7883 0.0601
7884 0.254
7885 0.229
7818 1.78
7907 3.82
7832 0.0172

FIG.9h



	IC50
7613	19.9
7616	1.24
7620	0.902
7689	120
7832	0.0156
5G1.1	0.0582
A233 (a-FP)	5.45

FIG.9i



	IC50
7832	0.0234
7879	0.123
7909	0.0167
7910	0.0201
7865	0.0214
7825	343159
7871	0.0366
7908	0.150
7834	0.0622
7890	0.0759

FIG.9j



Hemolytic Assay: AP, 20% normol Hu serum
% Hemolysis
nM Fab or Ab
Ser Hem
100
75
50
25
0
10
100
1000
7092
7831
7832
7875
7876
7877
7878
7086
5G1.1
A233 (a-FP)

FIG.10a



Hemolytic Assay; AP, 20% normal Hu serum
7086
7821
7822
7823
7824
7864
7865
7886
5G1.1
A233 (a-FP)
Ser Hem 100
% Hemolysis
0
25
50
75
100
10
100
1000
nM Fab or Ab

FIG.10b



Hemolytic Assay: AP, 20% normal Hu serum
7086
7887
7888
7889
????
7093
7833
7834
7835
7836
Ser Hem
100
75
50
25
0
% Hemolysis
10
100
1000
nM Fab or Ab

FIG.10c



Hemolytic Assay: AP, 20% normal Hu serum
Ser Hem 100
75
50
25
0
% Hemolysis
10
100
1000
nM Fab or Ab
7091
7829
7830
7871
7872
7873
7874
7086
5G1.1
A233 (a-FP)

FIG.10d



Hemolytic Assay: AP, 20% normal Hu serum
Ser Hem 100
% Hemolysis
0
25
50
75
100
0.1
1
10
100
1000
nM Fab or Ab
7880
7881
7882
7883
7884
7885
7832
5G1.1
A233 (α-FP)

FIG.10e



Hemolytic Assay: AP, 20% normal Hu serum
7909
????
7890
7832
5G1.1
A233 (a-FP)
% Hemolysis
nM Fab or Ab
Ser Hem
125
100
75
50
25
0
0.1
1
10
100
1000

FIG. 10f



Hemolytic Assay: AP, 100pM Cy C5
% Hemolysis
Ser Hem
100
75
50
25
0
0.001
0.01
0.1
1
10
nM Fab or Ab
7871
7872
7873
5G1.1
7086 IgG1AA
IC50
7871 0.111
7872 0.141
7873 0.158
5G1.1 1.71
7086 IgG1AA 0.0542

FIG.11a



Hemolytic Assay: AP, 100pM Cy C5
Ser Hem 100
75
50
25
0
% Hemolysis
0.001
0.01
0.1
1
10
nM Fab or Ab
7829
7830
N19/8
7086 IgG1AA
IC50
7829 1.40
7830 0.845
N19/8 0.661
7086 IgG1AA 0.0542

FIG.11b



Hemolytic Assay: AP, 100pM Cy C5
% Hemolysis
Ser Hem
100
75
50
25
0
0.001
0.01
0.1
1
10
nM Fab or Ab
7833
7834
7835
7890
7086 IgG1AA
IC50
7833 0.440
7834 0.147
7835 0.174
7890 0.562
7086 IgG1AA 0.0411

FIG.11c



Hemolytic Assay: AP, 100pM Cy C5
% Hemolysis
Ser Hem
100
75
50
25
0
0.001
0.01
0.1
1
10
nM Fab or Ab
7831
7832
7876
A233 (α-FP)
7086 IgG1AA
IC50
7831 0.149
7832 0.0664
7876 0.0776
A233 (α-FP) 11.4
7086 IgG1AA 0.0444

FIG.11d



Hemolytic Assay: AP, 100pM Cy C5
7878
7909
7910
7086 IgG1AA
IC50
7878 0.170
7909 0.0794
7910 0.119
7086 IgG1AA 0.0570
% Hemolysis
Ser Hem
100
75
50
25
0
0.001
0.01
0.1
1
10
nM Fab or Ab

FIG.11e




Hemolytic Assay: AP, 100pM Cy C5
7871
7829
7830
7908
N19/8
IC50
7871 0.137
7829 3.67
7830 1.78
7908 1.29
N19/8 1.22
Ser Hem
% Hemolysis
nM Fab or Ab
0
25
50
75
0.001
0.01
0.1
1
10

FIG.11f



	MOR08109	MOR08110	MOR08111	MOR08113	MOR08114	5G1.1
IC50	34.83	28.38	21.51	33.61	34.15	37.81

FIG.12



3SGI36_Hemolytic assay: CP, 5% cyno serum
MOR08109
MOR08110
MOR08111
MOR08113
MOR08114
5G1.1
% Hemolysis
100
75
50
25
0
1
10
100
1000
10000
nM Ab

FIG.13



Hemolytic Assay: AP, 100pM Hu C5
8109 IgG1AA
8110 IgG1AA
8111 IgG1AA
5G1.1 IgG2/4
Ser Hem
% Hemolysis
75
50
25
0
0.001
0.01
0.1
1
10
nM Ab

FIG.14a



Hemolytic Assay: AP, 100pM Hu C5
8113 IgG1AA
5G1.1 IgG24
Ser Hem
53
28
3
% Hemolysis
0.001
0.01
0.1
1
10
nM Ab

FIG.14b



Hemolytic Assay: AP, 100pM Hu C5
8114 IgG1AA
5G1.1 IgG2/4
% Hemolysis
0
25
50
0.001
0.01
0.1
1
10
nM Ab

FIG.14c



Hemolytic Assay: AP, 20% normal Hu Serum
8109 IgG1AA
8110 IgG1AA
8111 IgG1AA
5G1.1 IgG2/4
Ser Hem 100
75
50
25
0
% Hemolysis
1
10
100
1000
nM Ab

FIG.15a



Hemolytic Assay: AP, 20% normal Hu Serum
8113 IgG1AA
5G1.1 IgG2/4
Ser Hem 100
% Hemolysis
0
25
50
75
1
10
100
1000
nM Ab

FIG.15b



Hemolytic Assay: AP, 20% normal Hu Serum
8114 IgG1AA
5G1.1 IgG2/4
Ser Hem
100
75
50
25
0
% Hemolysis
10
100
1000
nM Ab

FIG.15c



C5a ELISA
8109 IgG1AA
8110 IgG1AA
8111 IgG1AA
5G1.1 IgG2/4
ng/ml C5a
Ser Hem
Baseline
nM Ab
3.0
2.5
2.0
1.5
1.0
0.5
0.0
1
10
100
1000

FIG.15d



C5a ELISA
8113 IgG1AA
5G1.1 IgG2/4
Ser Hem
ng/ml C5a
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Baseline
1
10
100
1000
nM Ab

FIG.15e



C5a ELISA
8114 IgG1AA
5G1.1 IgG2/4
ng/ml C5a
0
1
2
3
4
Ser Blnk
10
100
1000
nM Ab

FIG.15f



C5a-des-Arg ELISA
ng/ml C5a
2.0
1.5
1.0
0.5
0.0
Ser Hem
Baseline
1
10
100
1000
nM Fab or Ab
7092
7831
7832
7875
7876
7877
7878
7086
5G1.1
A233 (a-FP)

FIG.16a



C5a–des–Arg ELISA
7086
7821
7822
7823
7824
7864
7865
7866
5G1.1
A233 (a–FP)
ng/ml C5a
Ser Hem
Baseline
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
1
10
100
1000
nM Fab or Ab

FIG.16b



7086
7867
7868
7869
????
7093
7833
7834
7835
7836
C5a–des–Arg ELISA
Ser Hem
Baseline
ng/ml C5a
2.5
2.0
1.5
1.0
0.5
0.0
10
100
1000
nM Fab or Ab

FIG.16c




C5a-des-Arg ELISA
ng/ml C5a
Ser Hem
Baseline
2.0
1.5
1.0
0.5
0.0
10
100
1000
nM Fab or Ab
7091
7829
7830
7871
7872
7873
7874
7086
5G1.1
A233 (a-FP)

FIG.16d



	7091	7871	7872	7873	7874	7908
EC50	1.316	0.8489	0.7889	1.051	0.9620	1.321

FIG.17-1



6GHA18_QC ELISA:
MOR07091 + HCDR2- and LCDR3-derivates on cynoC5
RFU (430nm)
conc. (nM)
7091
7871
7872
7873
7874
7908
EC50 | 7091 | 7871 | 7872 | 7873 | 7874 | 7908
1.316 | 0.8489 | 0.7889 | 1.051 | 0.9620 | 1.321

FIG.17-2



6GHA18_QC ELISA:
MOR07091 + HCDR2- and LCDR3-derivates on huC3
7091
7871
7872
7873
7874
7908
RFU (430nm)
50000
45000
40000
35000
30000
25000
20000
15000
10000
5000
0
0.01
0.1
1
10
100
conc. (nM)

FIG.17-3



6GHA18_QC ELISA:
MOR07091 + HCDR2- and LCDR3-derivates on huC4
RFU (430nm)
50000
45000
40000
35000
30000
25000
20000
15000
10000
5000
0
0.01
0.1
1
10
100
conc. (nM)
7091
7871
7872
7873
7874
7908

FIG.17-4

MOR0	retained binding activity	0h	4h	8h
MOR07086	88.02%			
MOR07832	69.06%			
MOR07834	66.95%			
MOR07872	82.72%			
MOR07876	78.55%			
MOR07086	92.94%			
MOR07832	74.84%			
MOR07834	92.00%			
MOR07872	90.70%			
MOR07876	75.60%			
MOR07086	89.57%			
MOR07832	91.56%			
MOR07834	86.05%			
MOR07872	72.10%			
MOR07876	70.34%			




FIG. 18

Rows: unlabelled Fab (100-fold excess)	Columns: biotinylated Fab									
MOR0	7086	7832	7834	7871	7872	7873	7876	7878		
7086	691	2597	853	1191	825	694	1002	495		
7832	668	1186	404	586	3601	499	595	251		
7834	618	1727	391	625	609	455	756	560		
7871	426	1384	422	758	619	1009	392	451		
7872	1553	3199	773	1486	944	882	842	781		
7873	800	3342	965	1414	1491	922	1188	691		
7876	892	2535	652	978	1366	1394	621	701		
7878	850	2643	784	1228	2218	891	1180	643		
100%	36816	37112	37340	43250	41651	33768	38078	37405		
competition with identical Fab			biotinylated Fab without competition = 100% signal							

FIG.19



Chimeric Supernatant
C5
Chimeric C5 Binding
OD
1.7
1.6
1.5
1.4
1.3
1.2
1.1
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Fab/Mab
Blank
029-02
029-03
Quidel
MOR07090
MOR07094
MOR07085
MOR07093
MOR07092
MOR07091
MOR07089
MOR07088
MOR07087
MOR07086
MOR07084
MOR07083
MOR07082
MOR07081
MOR06961
MOR06952
MOR06763
MOR06757
MOR06756
MOR06525

FIG.20



Chimeric C5
Hu C5
Chimeric/Human C5 with 5G1.1 Capture
OD
0
1
2
3
4
MOR06525
MOR06756
MOR06757
MOR06763
MOR06952
MOR06961
MOR07081
MOR07082
MOR07083
MOR07084
MOR07086
MOR07087
MOR07088
MOR07089
MOR07091
MOR07092
MOR07093
MOR07085
MOR07094
MOR07095
MOR07090
Quidel
029-03
029-02

FIG.21



Alternative Pathway - Plate 1
% Hemolysis
nM Fab or Ab
0
25
50
75
100
0.1
1
10
100
1000
6525
6756
6757
6763
6952
6961
7081
7082
7083
Quidel a-FP
+ 6% HaMb C5 sup
C5-depleted serum

FIG.22-1



Alternative Pathway - Plate 2
% Hemolysis
0
25
50
75
100
1
10
100
1000
nM Fab or Ab
7084
7086
7087
7088
7089
7090
7091
7092
7093
Quidel α-C5
+ 6% HaMb C5 sup.
C5-depleted serum

FIG.22-2



Alternative Pathway – Plate 3
% Hemolysis
100
75
50
25
0
0.1
1
10
100
1000
nM Fab or Ab
7094
7095
????
+ 6% HaMb C5 sup
C5–depleted serum

FIG.22-3



6756
6557
6952
6961
7081
7082
7083
7084
7086
7087
(min) 0 30 60 90
7088
7089
7090
7091
7092
7093
7094
6525
ACZ885

Fig. 23



7089
6952
7083
6525
6557
6961
7091
7093
ACZ885
7094
7092
7088
7084
7086
7082
6756
7087
7081
7090
ACZ885

Fig. 24



7086
7086
7086-7821H
7086-7822H
7086-7823H
7086-7865L
7086-7866L
7086-7869L
Fraction Remaining
Min
110
100
90
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
60
70
80
90

FIG.25-1



7091
7091-7871L
7091-7872L
7091-7873L
7091-7874L
7091
250
200
150
100
50
0
0
10
20
30
40
50
60
70
80
90
Min

FIG.25-2



7092
7092
7092-7831H
7092-7832H
7092-7876L
7092-7878L
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
60
70
80
90
Min

FIG.25-3



7093
7093-7833H
7093-7834H
7093-7835H
7093-7836H
7093
Min
120
110
100
90
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
60
70
80
90

FIG.25-4



7086
7086-7865L
7086-7866L
Fraction Remaining
Min
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140

FIG.26-1



7091
7091-7829H
7091-7830H
7091-7871L
7091-7872L
7091-7873L
Fraction Remaining
Min
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140

FIG.26-2



7092-7831H
7092-7832H
7092-7876L
7092-7878L
7092-7909H
7092-7910H
7092
Fraction Remaining
Min
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140

FIG.26-3



7093-7833H
7093-7834H
7093-7835H
7093-7890H
7093
Fraction Remaining
Min
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
60
70
80
90

FIG.26-4



6525
% inhibition
100
90
80
70
60
50
40
30
20
10
0
1
10
100
1000
[CONC nM]
6756
% inhibition
100
90
80
70
60
50
40
30
20
10
0
1
10
100
1000
[CONC nM]

FIG.27